anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators seek to determine if women with a vitamin D serum concentration lower than 50 nmol/L and who regularly resistance train will improve strength performance outcomes when taking a daily supplement of 5000 IU of vitamin D3 over an 8-week period, as compared to the same demographic of women who do not take a daily supplement of vitamin D3. The participants will receive "Nature's Bounty Vitamin D3, 5,000 IU, soft gels" and the PI will be providing the supplement and the placebo. A pre-intervention data collection and screening (PRE) will be performed involving blood draw, food log, a body composition test (using Dual-energy X-ray absorptiometry \[DEXA\]), and a BioDex testing to determine maximal muscle strength. Following PRE testing, the participants will be divided into one of two groups: 1) taking a vitamin D3 supplement (n=20) or, 2) taking a placebo. The participants will be instructed to continue their resistance training regimen. Training will be logged and turned in to the PI weekly. The participants will perform a post-intervention data collection (POST), which includes the same test from PRE. Variables of interest will include changes in: 1) blood level of vitamin D, 2) muscle and fat mass, and 3) leg strength/power during the BioDex test.
Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility among women, and women with PCOS are at increased risk for pregnancy complications such as gestational diabetes and pre-eclampsia. Both hyperandrogenism (HA) and obesity exacerbated insulin resistance (IR) are characteristics of the syndrome, and are targets for treatment, but which should be the predominant focus is still unknown. Phase 1 of this study will be a randomized trial of three preconception interventions in infertile women with PCOS. The first arm will be a combined intervention of medication, meal replacements, and lifestyle modification to improve IR. Orlistat is a gastric lipase inhibitor that reduces the absorption of fat contained in a meal by about 30%. The second arm will be the use of a continuous OCP for 4 months to improve HA. Lo-Estrin 1/20 will be used in a continuous method for 4 months to suppress the ovary. The third arm is the combination of both to improve HA an IR. Phase II of this study will involve ovulation induction with clomiphene citrate with hopeful outcome of pregnancy. Finally, Phase III involve following the pregnancies for outcomes and complications.
NEW MATERIAL:The tricyclic alcohol of formula I (one of R1 and R2 is H and the other is 1-8C hydrocarbon group, or both R1 and R2 are 1-8C hydrocarbon group or together form a 2-6C ring; R3 is H or 1-8C hydrocarbon group). EXAMPLE:9-Exo-ethyltricyclo[5,2,1,0<2.6>]decan-8-ol. USE:Useful as a chilling agent. It has physiologically refreshing effect, and is almost odorless. It is used to impart a refreshing and chilling effect to cosmetics such as beauty wash, perfumery, cream, lotion, etc., a deodorant, an anhidrotic, cleaning agents such as soap, champoo, etc., drugs such as ointment, external anti-inflammatory nd analgesic agent, etc. and foods such as chewing gum, etc. PREPARATION:The compound of formula I can be prepared by reacting the compound of formula III derivaed from cyclopentadiene of formula II with a halide, reacting the produced compound of formula IV with the compound of formula R2X (X is halogen), and finally reacting with an organometallic reagent.
Other than usual medical care received by children, their parents in this group will receive three individual, face-to-face interventions on motivational interviewing by a trained registered nurse at baseline, 3-month and 6-month, with each session is about 60 minutes. All sessions of motivational interviewing will be scheduled based on the treatment schedule of the children and conducted in an interview room inside the pediatric oncology unit. A 25-30 minutes semi -structured interview will be conducted for process evaluation at 6-month.
PURPOSE:A very safe, inexpensive and effective purgative, obtained by reacting a specific amount of lactose as a main agent with lactic acid bacteria, e.g. Lactobacillus bifidus, and usable for keeping health or treating diseases for a long period. CONSTITUTION:A purgative obtained by at least >=30g lactose and one or two or more selected from live bacteria, spores and culture media of lactic acid bacteria, e.g. Lactobacillus bifidus, together. A cuture medium after fermentation of lactic acid bacteria, e.g. Lactobacillus bifidus, Bacillus natto and yeasts is directly dried to prepare semidried material or dried powder containing all of the live bacteria, spores and enzymes. The resultant material or powder can be used as a basic material. Lactic acid bacteria are multiplied by decomposing lactose, and Bacillus natto is multiplied by decomposing proteins. The yeasts are multiplied by decomposing polysaccharides. A large volume of CO2 gas is produced as a by-product in the process, and the physical pressure of the CO2 gas nontoxic to the human body and the stimulating action of the nascent CO2 gas are utilized to give the aimed purgative.
The investigator working hypothesis is an impairment of the cerebral venous drainage in IIH compared to the circulation observed in healthy volunteers considered as the reference. The research will focus on adult patients referred to the imaging department for intracranial hypertension assessment. MRI support is common for this type of request The reference will be established in a population of healthy volunteers for whom MRI blood flow measurements will be performed. In addition to the primary objective, the investigators assess the impact of IIH on CSF dynamics The study does not present any risk for the subject, any contraindication to MRI examination being respected. The subjects will undergo MRI examination including morphological and flow sequences without contrast injection. The flow sequences, in planes located at the C2-C3 and aqueductal levels, will be used to measure vascular flows (venous and arterial) and CSF oscillatory volumes. Image post-processing will be performed on a semi-automatic software allowing to extract fluid dynamics parameters.
The invention relates to a traditional Chinese medicine for treating scapulohumeral periarthritis, and provides a medicine for scapulohumeral periarthritis to solve the problem of scapulohumeral periarthritis treatment. The traditional Chinese medicine is prepared from Chinese angelica, Herba Ephedrae, radix paeoniae alba, notopterygium root, centipede, large-leaved gentian, pinellia tuber, semen brassicae, dried tangerine peel, radix bupleuri, monkshood, scorpion, root of membranous milk vetch, cassia twig and Cistanche according to a certain proportion. Chinese angelica enriches blood, invigorates blood circulation, clears and activates the channels and collaterals. Herba Ephedrae is used for wind-cold exterior syndrome of excess type, chest tightness, dyspnea with cough, wind edema, rheumatism with severe painful obstruction, Yin flat abscesses and subcutaneous nodule. Radix Paeoniae Alba stabilizes liver Yang, nourishes blood and restrains yin. Notopterygium root warms the kidney and activates yang, absorbs Qi and stops diarrhea. Centipede dispels wind, relieves convulsion, detoxifies, dissipates binds, relaxes vein and relieves pain. Large-leaved gentian dispels rheumatism, reduces asthenic heat and relieves pain. Pinellia tuber treats damp-phlegm cough, wind-phlegm dizziness, phlegm syncope headache, vomiting, nausea, distention and fullness in chest and gastral cavity, globus hysteriocus, goiter and tumor subcutaneous nodule, carbuncle and pyogenic infections. Semen brassicae activates Qi, sweeps phlegm, relieves swelling and relieves pain. Tangerine peel rectifies Qi, invigorates spleen, regulates the middle energizer, eliminates dampness and reduces phlegm. Scorpion reduces wind, relives spasm, counters toxic substances, dissipates binds, relaxes vein and removes pain. The above medicines can cure scapulohumeral periarthritis corporately.
INTRODUCTION: To date, radical surgery remains the best curative option in patients with early-stage lung cancer. In patients with small lung lesions, video-assisted thoracic surgery (VATS) should be increasingly chosen as a fundamental alternative to thoracotomy as it is associated with less postoperative pain and better quality of life. This scenario necessarily increases the need for thoracic surgeons to implement new localization techniques. The conventional near-infrared (NIR) indocyanine green (ICG) method demonstrated a significant limitation in deep cancer recognition, principally due to its intrinsic low-depth tissue penetration. Similarly, the lymph-node sentinel approach conducted by the ICG method was demonstrated to be inefficient, mainly due to the non-specificity of the tracker and the irregular pathway of pulmonary lymph node drainage. Our study aims to evaluate the effectiveness of Cetuximab- IRDye800CW in marking lung nodules and mediastinal lymph nodes.
METHODS AND ANALYSIS: This study is defined as an open-label, single-arm, single-stage phase II trial evaluating the effectiveness of Cetuximab-IRDye800CW in detecting tumors and lymph-node metastases in patients with lung cancer who are undergoing video-assisted thoracic surgery (VATS). Cetuximab is a monoclonal antibody that binds, inhibits, and degrade the EGFR. The IRDye® 800CW, an indocyanine-type NIR fluorophore, demonstrated enhanced tissue penetration compared to other NIR dyes. The combination with the clinical approved monoclonal antibody anti-epidermal growth factor EGFR Cetuximab (Cetuximab-IRDye800) has shown promising results as a specific tracker in different cancer types (i.e., brain, pancreas, head, and neck). The study's primary outcome is focused on the proportion of patients with lung nodules detected during surgery using an NIR camera. The secondary outcomes include a broad spectrum of items, including the proportion of patients with detection of unexpected cancer localization during surgery by NIR camera and the proportion of patients with negative surgical margins, the evaluation of the time spawns between the insertion of the NIR camera and the visualization of the nodule and the possible morbidity of the drug assessed during and after the drug infusion.
ETHICS AND DISSEMINATION: This trial has been approved by the Ethical Committee of Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino (Torino, Italy) and by the Italian Medicines Agency (AIFA). Findings will be written as methodology papers for conference presentations and published in peer-reviewed journals. The Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, the University of Torino, and the AIRC Public Engagement Divisions will help identify how best to publicize the findings.Trial registration EudraCT 202,100,645,430.
CLINICALTRIALS: gov NCT06101394 (October 23, 2023).
Reduced toxicity conditioning regimen with intravenous (i.v.)Busulphan (Busilvex), 12.8 mg/kg plus Fludarabine, 4 x 40 mg/m².
INTRODUCTION: Evidence suggests that delaying an appendicectomy for up to 24 hours does not increase the risk of complicated appendicitis. Appendicoliths are a risk factor for perforation. No study has explored the temporal relationship between appendicolith presence and time to perforation. In this retrospective cohort study, we hypothesise that the presence of an appendicolith confirmed on preoperative computerised tomography scan (pCT) leads to a shorter time to complicated appendicitis.
METHODS: We undertook a retrospective single-centre study of patients admitted between 2018 and 2020. Inclusion criteria included: age ≥18 years, appendicitis confirmed on histopathology following an operation and a pCT scan. Complicated appendicitis was defined intraoperatively as an appendicular abscess, gangrenous or perforated appendix.
RESULTS: Some 310 patients were included in the study. Forty-five per cent presented with complicated appendicitis (n = 138). Appendicoliths were present in 79 (25.5%) patients. Multivariate logistic regression identified an appendicolith as a significant risk factor for perforation (odds ratio 3.50, 95% confidence interval [CI] 1.16-10.59; p = 0.027). Within the first 12 hours of admission, patients with an appendicolith accounted for a significantly greater proportion of those with complicated appendicitis intraoperatively compared with those without (56.7% vs 43.3%, respectively; p = 0.003). Within 12 hours of admission, those with an appendicolith were 2.05 times more likely to suffer from complicated appendicitis than those without (95% CI 1.28-3.29).
CONCLUSIONS: Patients with an appendicolith appendicitis should be considered for an early appendicectomy. Future large-scale multicentre prospective studies are required to explore this further, perhaps informing future guidelines.
The invention belongs to biological pharmacy technical field, does is it specifically related to a kind of targeting PD-L1 with anti-tumor activity? the affinity peptide S10 product of IgV and preparation thereof and application. Does this affinity peptide S10 specifically bind to PD-L1? IgV district, its aminoacid sequence is WSHGGHQHFIRF, and molecular weight is 1507.7. Affinity peptide S10 is prepared by Fomc solid phase polypeptide synthesis, plays a role as main active in preparing drugs against colon cancer. Is affinity peptide S10 provided by the present invention by utilizing phage display peptide library triage techniques, with PD-L1? IgV is that target spot carries out high flux screening acquisition. Do be inventor by lotus tumor experiment in Mice Body, it was demonstrated that affinity peptide S10 has good anti-tumor activity, can substantially suppress the growth of mouse interior tumor, thus being based on PD-L1? drug research and development new thinking and theoretical basis are provided.
TPs in the THPP-I group receive, in addition to enhanced usual care (EUC), between 6 to 14 sessions of THPP (simple cognitive behaviour therapy) starting from their recruitment in the second/ third trimester until up to 6 months after child birth. Sessions will be delivered by peers on an individual basis at a location of convenience to the TPs.
The following adverse reactions have been identified during post-approval use of FASLODEX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

For FASLODEX 250 mg, other adverse reactions reported as drug-related and seen infrequently (<1%) include thromboembolic phenomena, myalgia, vertigo, leukopenia, and hypersensitivity reactions, including angioedema and urticaria.

Vaginal bleeding has been reported infrequently (<1%), mainly in patients during the first 6 weeks after changing from existing hormonal therapy to treatment with FASLODEX. If bleeding persists, further evaluation should be considered.

Elevation of bilirubin, elevation of gamma GT, hepatitis, and liver failure have been reported infrequently (<1%).
Substances Decreasing the Systemic Exposure of CHCs and Potentially Diminishing the Efficacy of ANNOVERA: Table 3 includes substances that demonstrated an important drug interaction with CHCs.

Substances Increasing the Systemic Exposure of CHCs and Potentially Increasing Exposure to Estrogen and/or Progestin in ANNOVERA: Co- administration of atorvastatin or rosuvastatin and certain CHCs containing EE increase systemic exposure of EE by approximately 20–25%. Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase systemic exposure of the estrogen and/or progestin component of ANNOVERA.

Human Immunodeficiency Virus (HIV)/ Hepatitis C Virus (HCV) Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors: Significant decreases in systemic exposure of estrogen and/or progestin have been noted when CHCs are co-administered with some HIV protease inhibitors (eg, nelfinavir, ritonavir, darunavir/ritonavir, (fos)amprenavir/ritonavir, lopinavir/ritonavir, and tipranavir/ritonavir), some HCV protease inhibitors (eg, boceprevir and telaprevir), and some non-nucleoside reverse transcriptase inhibitors (eg, nevirapine).

In contrast, significant increases in systemic exposure of estrogen and/or progestin have been noted when CHCs are co-administered with certain other HIV protease inhibitors (eg, indinavir and atazanavir/ritonavir) and with other non-nucleoside reverse transcriptase inhibitors (eg, etravirine).
Subjects will be randomized to receive either CC-220 + Pola (polatuzumab vedotin) + Ritux (rituximab) or polatuzumab vedotin + bendamustine + rituximab in 21-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study. Polatuzumab vedotin and rituximab will be administered at the same levels as in part 1. Bendamustine will be given to subjects randomized in the control arm at a dose of 90 mg/m2 IV on Days 1 and 2 of each of the first 6 cycles.
<P>PROBLEM TO BE SOLVED: To provide a technique of moistening the skin by bringing the fabric having germanium deposited by sputtering into contact with the skin or by positioning it near the skin.  <P>SOLUTION: The fabric has the germanium or a germanium alloy deposited thereon by sputtering. For the germanium alloy, Ge-In, Ge-Sn, Ge-Ti, Ge-Fe, Ge-Si, Ge-Si-Ti, Ge-In-Ti, etc. are mentioned. The germanium content of the alloy is preferably 50 mass% or more. As for sputtering, so-called low-temperature sputtering is preferable. The low-temperature sputtering is executed by keeping a distance of about 5 cm or more from the target fabric so that the temperature of the fabric may not rise so much. The sputtering temperature is normally 50-250°C, preferably 100-180°C, and the vacuum is normally 1×10-2 to 1×10-6, preferably 1×10-3 to 1×10-5. The thickness of a sputtering film thus formed is normally 50-300 nm, preferably 80-150 nm. Sputtering may be applied to either one side of the fabric alone or both sides thereof. In the case of woven fabric, the sputtering may be conducted after fabric is woven, while fibers subjected to the sputtering may be woven into the fabric as well.  <P>COPYRIGHT: (C)2004,JPO
Chlorpyrifos (CPF) is a widely used organophosphate insecticide that has been linked to detrimental health effects that range from neurological impacts to respiratory disease. The objective of this study was to assess respiratory symptoms associated with CPF exposure throughout the application season. Urine samples were collected from Egyptian adolescent applicators (n = 206) and non-applicators (n = 72) to assess 3,5,6-trichloro-2-pyridinol (TCPy), a biomarker for CPF exposure, along with spirometry measures to determine lung ventilatory function. Samples were collected over 7 months in 2016. Logistic regression was used to model the odds of reporting wheeze symptoms based on urinary TCPy concentrations while controlling for age and smoking in the household. Ordinal multinomial logistic regression was used to model the percent reference for forced expiratory volume in one second (rFEV1) based on urinary TCPy concentration (µg/g creatinine). Wheezing increased with increasing pesticide exposure (OR = 1.74 (1.32 - 2.31)). There was no statistically significant relationship between rFEV1 and TCPy concentration. Efforts to reduce pesticide exposure should be implemented to prevent the potential onset or exacerbation of any linked respiratory complications in adolescents.
PURPOSE:To obtain a bathing agent composition, having high cloudiness in pouring thereof into bath water and capable of exhibiting preventive effects on settling of titanium dioxide by using the titanium dioxide and an acylamino acid salt together as a clouding agent and combining both with sodium carbonate. CONSTITUTION:A bathing agent composition is obtained by using titanium dioxide and an acylamino acid salt as a clouding agent in coexistence with sodium carbonate. The aforementioned composition is excellent in dispersion stability. The molar ratio of the acylamino acid salt to the sodium carbonate is preferably 0.016-1.50. The above-mentioned bathing agent composition rapidly assumes cloudy color in dispersion thereof in bath water to provide an image of a cow's milk bath from the color tone, causes skin care or a comfortable mood of eliminating stress and is capable of physically and mentally affording relaxed feeling. The persistence of the cloudy state is excellent and settling of the titanium dioxide can be prevented without roughening the bathtub bottom.
PCT No. PCT/US93/05122 Sec. 371 Date Dec. 23, 1994 Sec. 102(e) Date Dec. 23, 1994 PCT Filed May 28, 1993 PCT Pub. No. WO93/24112 PCT Pub. Date Dec. 9, 1993In accordance with the present invention, it has been discovered that a major reason for the failure to achieve successful in vivo transplantation in large mammalian species has been flaws associated with the design of microcapsules taught in the prior art, flaws in the method of making such microcapsules, and a lack of tests to determine if a given microcapsule will be successful. In accordance with the present invention, a number of functional properties which must be met by a microcapsule in order to achieve successful in vivo transplantation in large animal models have been identified. These properties include (i) a mechanically stable capsule core, (ii) a mechanically strong capsule membrane (i.e., the membrane must be of sufficient strength to prevent capsule disruption), (iii) the absence of excess exposed positively-charged PLL (which leads to fibrosis), and (iv) an adequate level of diffusion of the entrapped biologically active material out of the capsule.
OBJECTIVES: Coptisine (Cop), an alkaloid isolated from Rhizoma Coptidis, has a protective effect against central nervous system diseases such as cerebral ischaemia-reperfusion (IR). Dysregulations in fatty acids metabolism are associated with neuroprotection and neuroinflammation. However, the effect of Cop on fatty acids metabolomics during anti-IR remains unclear.
METHODS: Cerebral IR rats were established by middle cerebral artery occlusion, and the therapeutic effect of Cop was evaluated by 2, 3, 5-triphenytetrazolium chloride staining and neurological deficits scores. By liquid chromatography-tandem mass spectrometry (LC-MS/MS), fatty acids metabolomics analysis in ischaemic hemisphere and serum were investigated.
RESULTS: We observed Cop (2 mg/kg/qd) was able to reduce cerebral infarct size and ameliorate the neurological function score. Meanwhile decrease in tumour necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) after Cop treatment. Compared with control, down-regulation of cyclopentenone PGs (e.g., PGA2, PGJ2, and 15-deoxy- delta-12,14-PGJ2) was observed in cerebral IR, but upregulation of them when followed by Cop treatment. Similarly, we found the ratios of 14,15-dihydroxyeicosatrienoic acid(14,15-DHET)/arachidonic acid and 11,12-DHET/arachidonic acid was lower in cerebral IR injury relative to control, while their ratios were increased after Cop treatment.
CONCLUSION: Our results indicated that Cop protect against cerebral IR injury, and its mechanism might be closely associated with antiinflammation and the regulation of arachidonic acid metabolism.